AFP AFT Pharmaceuticals Limited
Healthcare · Drug Manufacturers - Specialty & Generic
· website
· 126 employees
$4.01
52wk 2.20 – 4.13
Overall
—
Value
—
Growth
—
Health
—
Quality
—
Momentum
—
Dividend
—
Price
About AFT Pharmaceuticals Limited
AFT Pharmaceuticals Limited, together with its subsidiaries, develops, markets, and distributes pharmaceutical products in New Zealand, Australia, Asia, and internationally. The company offers proprietary and in-licensed products, including patented, branded, and generic drugs; and products for use in the areas of allergy, cold and flu, digestive health, eye care, first aid, natural health, pain management, skin care, sleeping aids, supplements, and other products. It has a research and development collaboration with Hyloris Pharmaceuticals SA for the development of the Maxigesic IV product. AFT Pharmaceuticals Limited was incorporated in 1997 and is headquartered in Auckland, New Zealand.
Fundamental trends
Financial statements
Loading…
Key metrics
Market cap
$420.51M
P/E (trailing)
33.42
P/E (forward)
24.65
EPS (trailing)
0.12
Dividend yield
0.3%
Payout ratio
8.5%
Beta
0.47
EV / EBITDA
19.00
Price / Book
4.57
ROE
13.7%
Operating margin
14.1%
Net margin
5.8%
Total cash
$10.24M
Total debt
$54.11M
Current ratio
2.24
Debt / Equity
0.50
Free cash flow
$-20.96M
Avg volume
2,825
Latest annual results
(FY ending 31 Mar 2026)
- Revenue$251.19M
- Gross profit$107.04M
- Operating income$17.23M
- Net income$14.73M
- Diluted EPS—
- Free cash flow-$19.30M
- Net debt$43.87M